Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Diabetes drug defeats Alzheimer’s

A drug created to treat type 2 diabetes has shown an ability to reverse Alzheimer’s-related memory loss in mice, according to researchers at Lancaster University in England.

The drug, not named in the university’s report, is a triple threat; it combines three hormones that act as growth factors. While the hormones can help the pancreas deal with sugar, they also appear to restore brain cells under attack by Alzheimer’s-causing processes.

Persons with type 2 diabetes are statistically at greater risk of developing Alzheimer’s.

The drug was tested on mice genetically engineered to develop Alzheimer’s. After taking the concoction daily for two months, mice could better retain memories of the path through a maze than those not dosed. The treated mice also showed fewer protein clumps and tangles among their brain cells, a signature of the disease.

TRENDPOST: Liraglutide, an older diabetes drug, already is in human trials as an Alzheimer’s treatment. Tests of the new three-part drug could begin within three years.